

### REMARKS

Claims 271-276 are pending. Claims 1-270 and 277-279 have been canceled.

With regards to the "First Election," the Applicant elects "macular degeneration" for search purposes. Claims 271-273 and 276-279 read on the species elected. The Applicant understands that upon allowance of a generic claim, he will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim. See 37 CFR 1.141.

Further, with regards to the "Second Election," the Applicant respectfully requests clarification as to why the Examiner has limited the "second drug" recited in claims 277-279 to the compounds disclosed on pages 23-70 of the instant application, as no such limitation appears in the claims. The Applicant respectfully traverses this portion of the Restriction. However, to solely to expedite prosecution, claims 277-279 has been canceled, thereby rendering moot the need for the second election of species (i.e. a second drug).

The Applicant believes no fees are due in connection with this filing. Nevertheless, the Commissioner is hereby authorized to charge any additional fees due in connection with the filing of this Response, or any other submission, to our Deposit Account, No. **06-1448**, Reference, **H MV-091.02**.

If a telephone conversation would expedite prosecution of the above-identified application, the Examiner is urged to contact the undersigned.

Date: July 17, 2009

155 Seaport Boulevard  
Boston, MA 02210  
Telephone: (617) 832-1000  
Telecopier: (617) 832-7000

Respectfully submitted,  
FOLEY HOAG LLP

By: /Jacob I. Wasserman/

---

Jacob I. Wasserman, Ph.D.  
Reg. No. 56,929  
Agent for Applicants